Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...

Descripció completa

Dades bibliogràfiques

Autors principals:	Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun
Format:	Artigo
Idioma:	Inglês
Publicat:	Korean Association for the Study of Intestinal Diseases 2025-10-01
Col·lecció:	Intestinal Research
Matèries:	upadacitinib vedolizumab combination therapy ulcerative colitis crohn disease
Accés en línia:	http://irjournal.org/upload/pdf/ir-2024-00174.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!